origin"'3 and the adult respiratory distress syndrome. 14 It has been suggested more recently that activation ofthe immune coagulation system with resultant induction ofmonocyte/endothelial cell procoagulant activity may be responsible for the vasculitic and thrombotic lesions seen in Crohn's disease,'5 neoplasia,'6 and the thrombogenicity of hypertonic total parenteral nutrition solutions'7"'9 submitted data.
It was recognised by Addison, over a century ago, that white blood cells were able to initiate coagulation,20 although the mechanism for the induction and modulation of the cellular procoagulant pathways have awaited more recent elucidation.
Although the kinetics and absolute cellular requirements for induction of monocyte/ macrophage procoagulant activity subtly vary with the nature of the inducing stimulus, the cellular procoagulant pathway is, in [30] [31] [32] [33] [34] Our work in this area has resulted in the description of two potential therapeutic modalities that strongly inhibit induction of procoagulant activity, in vitro and in vivo, whose effects may help to provide further information into the role of procoagulant activity and limit its activity in a variety of diseases.5 I79 The first is E series prostaglandins, the administration of which has led to abrogation of fulminant hepatitis in mice and man.535 In parallel with the marked clinical improvement, abrogation of procoagulant activity was observed. Secondly, we have now shown that lipid emulsion potently inhibits both monocyte and endothelial cell procoagulant activity induced by hypertonic total parenteral nutrition solutions and bacterial lipopolysaccharide in vitro. [17] [18] [19] It appears that the inhibition of procoagulant activity is mediated by free fatty acids hydrolysed by the emulsified triglyceride. These early results suggest a simple method of minimising total parenteral nutritioninduced thrombosis, -that is, by the concurrent administration of these two solutions.
Study of the cellular procoagulant pathway, as a mediator of disease, has caused us to alter our perspective of many apparently diverse pathologies, and in particular those related to our own field of gastroenterology. Rather than regarding them in isolation, we now see them as diseases of specific aetiology, mediated to a large extent through a final common pathway -that is, an occlusive ischaemia in association with disruption of the endothelium as a physiological interface. This perception suggests to us that by the capacity of therapeutic agents to influence cellular procoagulant activity, their potential in the treatment of a wide spectrum of diseases is very real.
Furthermore, rather than equating the efficacy of these drugs simply with the histological and physiological improvement that they confer, we may measure their activity against a principle effector mechanism of the disease. Ongoing studies in our laboratories are now in progress to define the molecular basis of their activity which will help further our understanding of the pathophysiology of disease and to devise more effective therapeutic strategies. 
